EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH

Bradley S Miller iD, Joanne C Blair, Michael Højby Rasmussen iD, Aristides Maniatis, Jun Mori iD, Volker Böttcher, Ho-Seong Kim, Rikke Beck Bang, Michel Polak, Reiko Horikawa iD

The Journal of Clinical Endocrinology & Metabolism · 2023

DOI: 10.1210/clinem/dgad394 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2023. Verfasst von Bradley S Miller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children's Hospital, Minneapolis, MN 55454, USA. Hauptthemen laut MEDLINE: Human Growth Hormone, Dwarfism, Pituitary. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Somapacitan is a long-acting GH derivative for treatment of GH deficiency (GHD).

Objective

Evaluate the efficacy and tolerability of somapacitan in children with GHD after 2 years of treatment and after the switch from daily GH.

Design

A randomized, multinational, open-labelled, controlled parallel group phase 3 trial, comprising a 52-week main phase and 3-year safety extension (NCT03811535).

Setting

Eighty-five sites across 20 countries. Patients A total of 200 treatment-naïve prepubertal patients were randomized and exposed; 194 completed the 2-year period.

Interventions

Patients were randomized 2:1 to somapacitan (0.16 mg/kg/wk) or daily GH (0.034 mg/kg/d) during the first year, after which all patients received somapacitan 0.16 mg/kg/wk. Main outcome measures Height velocity (HV; cm/year) at week 104. Additional assessments included HV SD score (SDS), height SDS, IGF-I SDS, and observer-reported outcomes.

Results

HV was sustained in both groups between 52 and 104 weeks. At week 104, mean (SD) for HV between weeks 52 and 104 was 8.4 (1.5) cm/year after continuous somapacitan treatment and 8.7 (1.8) cm/year after 1 year of somapacitan treatment following switch from daily GH. Secondary height-related endpoints also supported sustained growth. Mean IGF-I SDS during year 2 was similar between groups and within normal range (−2 to +2). Somapacitan was well tolerated, with no safety or tolerability issues identified. GH patient preference questionnaire results show that most patients and their caregivers (90%) who switched treatment at year 2 preferred once-weekly somapacitan over daily GH treatment.

Conclusions

Somapacitan in children with GHD showed sustained efficacy and tolerability for 2 years, and after switching from daily GH. Patients/caregivers switching from daily GH expressed a preference for somapacitan. Clinical Trial Registration NCT03811535

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneDwarfism, PituitaryHumansChildInsulin-Like Growth Factor IGrowth HormoneGrowth DisordersBody HeightHistidineMannitolPhenol

Stichwörter der Autor:innen

growth hormonegrowth hormone deficiencygrowth hormone replacement therapylong-acting growth hormonesomapacitan

Substanzen

Insulin-Like Growth Factor IHuman Growth HormoneGrowth HormonesomapacitanHistidineMannitolPhenol

Autor:innen und Institutionen

  • Division of Pediatric Endocrinology, University of Minnesota Medical School, MHealth Fairview Masonic Children's Hospital, Minneapolis, MN 55454, USA.
  • Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, L14 5AB, UK.
  • Clinical Drug Development, Novo Nordisk A/S, Søborg 2860, Denmark.
  • Rocky Mountain Pediatric Endocrinology, Centennial, 80112 CO, USA.
  • Division of Pediatric Endocrinology and Metabolism, Children's Medical Center, Osaka City General Hospital, Osaka 534-0021, Japan.
  • Division of Pediatric Endocrinology and Metabolism, MVZ Endokrinologikum Frankfurt am Main, Frankfurt 60596, Germany.

ORCID-Profile: Bradley S Miller, Michael Højby Rasmussen, Jun Mori, Reiko Horikawa

Zitieren

APA

Miller, B. S., Blair, J. C., Rasmussen, M. H., Maniatis, A., Mori, J., Böttcher, V., Kim, H. S., Bang, R. B., Polak, M., & Horikawa, R. (2023). Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad394

Vancouver

Miller BS, Blair JC, Rasmussen MH, Maniatis A, Mori J, Böttcher V, et al. Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH. The Journal of Clinical Endocrinology & Metabolism. 2023. doi:10.1210/clinem/dgad394

BibTeX
@article{Miller2023,
  author = {Miller, Bradley S and Blair, Joanne C and Rasmussen, Michael Højby and Maniatis, Aristides and Mori, Jun and Böttcher, Volker and Kim, Ho-Seong and Bang, Rikke Beck and Polak, Michel and Horikawa, Reiko},
  title = {Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  doi = {10.1210/clinem/dgad394}
}
Kostenlos starten →